Ruth Peters1, Joanna Collerton, Antoneta Granic, Karen Davies, Thomas Kirkwood, Carol Jagger. 1. aImperial Clinical Trials Unit, School of Public Health, St Mary's Campus, Imperial College London bInstitute of Health and Society cInstitute for Cell and Molecular Biosciences, Newcastle University dNewcastle University Institute for Ageing, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.
Abstract
OBJECTIVES: Older adults are a fast growing group in society and are at high risk of hypertension, cognitive decline and dementia. Antihypertensive drugs, particularly calcium channel blockers (CCB), have been associated with a decreased risk of cognitive decline and dementia. We used observational data to examine the association between antihypertensive drug class and change in cognitive function. METHODS: The Newcastle 85+ Study is a population-based cohort study recruiting individuals aged 85 (born in 1921) via general/family practices in Newcastle/North Tyneside, United Kingdom. Data, including blood pressure, antihypertensive drug use and cognitive function [assessed using the Standardized Mini-Mental State Exam (SMMSE)], were collected at baseline and 3-year follow-up. RESULTS: The study population comprised 238 participants with a diagnosis of hypertension, prescribed antihypertensive drug treatment and with baseline and follow-up SMMSE assessment. There was an association between CCB use and less cognitive decline over 3 years (rate of decline was lower by 1.29 SMMSE points (95% confidence interval 0.16-2.42; P = 0.03) compared with those taking other antihypertensive classes after adjustment for age, sex, years of education, baseline SMMSE score, smoking, BMI, baseline blood pressure, and incident cerebrovascular event. This finding was even stronger in the cognitively intact (SMMSE >24), wherein rate of cognitive decline was lower by 1.33 SMMSE points (95% confidence interval 0.30-2.37; P = 0.01), but was not seen for other antihypertensive classes. CONCLUSION: Findings provide support for an association between CCB use and a lower rate of cognitive decline in very old adults with hypertension.
OBJECTIVES: Older adults are a fast growing group in society and are at high risk of hypertension, cognitive decline and dementia. Antihypertensive drugs, particularly calcium channel blockers (CCB), have been associated with a decreased risk of cognitive decline and dementia. We used observational data to examine the association between antihypertensive drug class and change in cognitive function. METHODS: The Newcastle 85+ Study is a population-based cohort study recruiting individuals aged 85 (born in 1921) via general/family practices in Newcastle/North Tyneside, United Kingdom. Data, including blood pressure, antihypertensive drug use and cognitive function [assessed using the Standardized Mini-Mental State Exam (SMMSE)], were collected at baseline and 3-year follow-up. RESULTS: The study population comprised 238 participants with a diagnosis of hypertension, prescribed antihypertensive drug treatment and with baseline and follow-up SMMSE assessment. There was an association between CCB use and less cognitive decline over 3 years (rate of decline was lower by 1.29 SMMSE points (95% confidence interval 0.16-2.42; P = 0.03) compared with those taking other antihypertensive classes after adjustment for age, sex, years of education, baseline SMMSE score, smoking, BMI, baseline blood pressure, and incident cerebrovascular event. This finding was even stronger in the cognitively intact (SMMSE >24), wherein rate of cognitive decline was lower by 1.33 SMMSE points (95% confidence interval 0.30-2.37; P = 0.01), but was not seen for other antihypertensive classes. CONCLUSION: Findings provide support for an association between CCB use and a lower rate of cognitive decline in very old adults with hypertension.
Authors: Thomas Polak; Martin J Herrmann; Laura D Müller; Julia B M Zeller; Andrea Katzorke; Matthias Fischer; Fabian Spielmann; Erik Weinmann; Leif Hommers; Martin Lauer; Andreas J Fallgatter; Jürgen Deckert Journal: J Neural Transm (Vienna) Date: 2017-09-01 Impact factor: 3.575
Authors: Ruth Peters; Sevil Yasar; Craig S Anderson; Shea Andrews; Riitta Antikainen; Hisatomi Arima; Nigel Beckett; Joanne C Beer; Anne Suzanne Bertens; Andrew Booth; Martin van Boxtel; Carol Brayne; Henry Brodaty; Michelle C Carlson; John Chalmers; Maria Corrada; Steven DeKosky; Carol Derby; Roger A Dixon; Françoise Forette; Mary Ganguli; Willem A van Gool; Antonio Guaita; Ann M Hever; David B Hogan; Carol Jagger; Mindy Katz; Claudia Kawas; Patrick G Kehoe; Sirkka Keinanen-Kiukaanniemi; Rose Ann Kenny; Sebastian Köhler; Setor K Kunutsor; Jari Laukkanen; Colleen Maxwell; G Peggy McFall; Tessa van Middelaar; Eric P Moll van Charante; Tze-Pin Ng; Jean Peters; Iris Rawtaer; Edo Richard; Kenneth Rockwood; Lina Rydén; Perminder S Sachdev; Ingmar Skoog; Johan Skoog; Jan A Staessen; Blossom C M Stephan; Sylvain Sebert; Lutgarde Thijs; Stella Trompet; Phillip J Tully; Christophe Tzourio; Roberta Vaccaro; Eeva Vaaramo; Erin Walsh; Jane Warwick; Kaarin J Anstey Journal: Neurology Date: 2019-12-11 Impact factor: 9.910